Windtree Therapeutics, Inc. (WINT)
After hours:
- GlobeNewswire
Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent
New Patent Provides Intellectual Property Protection Through Late 2039WARRINGTON, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11197869, covering the intravenous delivery of istaroxime for the treatment of acute heart failure. Th
- GlobeNewswire
Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic Innovation
Windtree Is Studying Istaroxime in Early Cardiogenic Shock PatientsWARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the results of U.S. hospital claims data analysis showing hospital inpatient mortality and length of hospital stay for cardiogenic shock patients. Cardiogenic shock is a serious condition tha
- GlobeNewswire
Windtree Therapeutics Reports Third Quarter 2021Â Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended September 30, 2021 and provided key business updates. “I am very pleased to report on another productive quarter for Windtree. We continue to make progress with istaroxime, our lead clinical product candidate, and
